Advanced or Metastatic Breast Cancer Clinical Trial
Official title:
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Eligible patients will be those patients who have had disease progression on at least 2 previous lines of endocrine therapies given for the treatment of metastatic disease or disease progression within 6 months of starting first line treatment for metastatic disease with an endocrine therapy combined with a CDK4/6 inhibitor. All patients must have historically confirmed HR positive (either estrogen receptor and/or progesterone receptor positive), HER2-low (defined as IHC2+/ISH- and IHC 1+) or HER2 IHC >0 <1+ expression, as determined by central laboratory testing results, advanced or metastatic breast cancer. The study aims to evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy. This study aims to see if trastuzumab deruxtecan allows patients to live longer without the cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the cancer affects patients' quality of life. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00748553 -
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05187832 -
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT01625286 -
Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05932667 -
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT05519059 -
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04742153 -
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
|
Phase 2 | |
| Not yet recruiting |
NCT06201234 -
Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
|
Phase 2 | |
| Completed |
NCT02154776 -
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
|
Phase 1 | |
| Active, not recruiting |
NCT03767335 -
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT06105632 -
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
|
Phase 3 | |
| Completed |
NCT01676753 -
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 |